Trial Profile
A Study for Testing Efficacy and Safety of the Administration of Vescell(TM) (Blood-Borne Autologous Angiogenic Cell Precursors) to Alleviate Anginal Symptoms and Myocardial Ischemia in Severe Anginal Syndrome +/- Heart Failure
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ACP 01 (Primary)
- Indications Angina pectoris; Myocardial ischaemia
- Focus Adverse reactions
- Sponsors TheraVitae
- 05 Jun 2014 New trial record